Please sign in to follow a disease.
Frontotemporal dementia
MONDO:0017276Frontotemporal dementia (FTD) comprises a group of neurodegenerative disorders, characterized by progressive changes in behavior, executive dysfunction and language impairment, as a result of degeneration of the medial prefrontal and frontoinsular cortices. Four clinical subtypes have been identified: semantic dementia, progressive non-fluent aphasia, behavioral variant FTD and right temporal lobar atrophy.
Also known as: FTD, MSTD, frontotemporal lobe dementia (FLDEM)
307 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Neurodegenerative drug study ends early after only 17 participants
Disease control TerminatedThis study was designed to let people who had already taken latozinemab in an earlier study continue receiving the drug. Only 17 people took part, and the study was stopped early. The goal was to track safety and how long people stayed on treatment, not to test if the drug could …
Phase: PHASE3 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Hope for genetic dementia: AL001 trial ends early
Disease control TerminatedThis phase 3 study tested a drug called AL001 in 119 people who carry a mutation in the progranulin gene, putting them at high risk for or already diagnosed with frontotemporal dementia. The goal was to see if AL001 could slow the worsening of memory, behavior, and language probl…
Phase: PHASE3 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Mental health sessions may boost vaccine uptake in latinx communities
Prevention TerminatedThis study tested whether adding vaccine discussions to routine behavioral health visits could reduce hesitancy and increase COVID-19 and flu shots among Latinx adults with mental illness. Clinicians used motivational interviewing and could offer a warm handoff to a nurse for vac…
Phase: NA • Sponsor: Boston College • Aim: Prevention
Last updated Jun 26, 2026 17:00 UTC
-
Smartphone app aims to ease burden for hispanic dementia caregivers
Symptom relief TerminatedThis study tests a mobile telehealth app called Brain CareNotes designed to help unpaid Hispanic caregivers manage challenging behaviors in people with Alzheimer's or related dementias. The app offers coaching and tools to handle symptoms like agitation or wandering. Researchers …
Phase: NA • Sponsor: Indiana University • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Dementia agitation drug trial halted after just 5 patients
Symptom relief TerminatedThis study tested a fast-dissolving film (BXCL501) placed under the tongue to quickly reduce severe agitation in older adults with dementia. The trial aimed to enroll many participants but was stopped early after only 5 people joined. Because it ended so soon, we cannot draw reli…
Phase: PHASE2 • Sponsor: BioXcel Therapeutics Inc • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Experimental drug aims to curb disinhibition in dementia patients
Symptom relief TerminatedThis study tested a drug called AVP-786 to see if it could safely reduce disinhibition—impulsive or inappropriate behavior—in people with neurodegenerative disorders like Alzheimer's or frontotemporal dementia. The trial planned to include many participants but was terminated ear…
Phase: PHASE2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Touchscreen device aims to give voice to dementia patients
Symptom relief TerminatedThis study tested a personalized touchscreen device (My PATI) to help people with Alzheimer's or related dementias communicate their care preferences. The goal was to improve quality of life for both patients and their caregivers. The study was terminated early, so results are li…
Phase: NA • Sponsor: Florida International University • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
New drug aimed at treating apathy in dementia patients tested
Symptom relief TerminatedThis study tested a drug called CVL-871 to see if it is safe and can help reduce apathy (lack of motivation or interest) in people with dementia. The trial included 41 participants with mild to moderate dementia and clinically significant apathy. The main goal was to check for si…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Could a Head-Zap at home boost your brain?
Symptom relief TerminatedThis study tested whether a gentle, non-invasive brain stimulation technique (tDCS) done at home, along with computer-based brain games, could improve thinking and language skills in people with primary progressive aphasia, mild cognitive impairment, or dementia. Participants use…
Phase: NA • Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Robot seal calms dementia patients during care
Symptom relief TerminatedThis study tested whether a robotic seal named PARO could help elderly people with moderate to severe memory problems feel calmer during daily care like bathing. The robot was used for a few minutes before and during care, twice a week for 16 weeks. The goal was to see if it redu…
Phase: NA • Sponsor: Centre Hospitalier Departemental Vendee • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Mental health study aims to uncover Long-Term heart risks
Knowledge-focused TerminatedThis study followed 167 adults with mental health issues like anxiety, depression, or sleep problems who visited their primary care doctor. Researchers used health conversations and a blood test to track lifestyle changes and heart disease risks over up to 20 years. The goal was …
Phase: NA • Sponsor: Region Skane • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Home help for dementia caregivers: study ends early with few answers
Knowledge-focused TerminatedThis study aimed to see if introducing formal home help (like a paid aide) improves the quality of life for people caring for elderly relatives with memory or thinking problems. Researchers planned to follow 12 caregivers for 90 days, measuring changes in their well-being, stress…
Sponsor: Groupe Hospitalier de la Region de Mulhouse et Sud Alsace • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC